• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation

    New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation

  2. UPDATE: Owens-Illinois surges on deal; DuPont falls after defeating Trian

    UPDATE: Owens-Illinois surges on deal; DuPont falls after defeating Trian

  3. FDA panel backs Vertex cystic-fibrosis drug Orkambi

    FDA panel backs Vertex cystic-fibrosis drug Orkambi

  4. Cystic Fibrosis Foundation Issues Statement on The New England Journal of Medicine Study on the Benefits of the Ivacaftor/Lumacaftor Combination Drug (Orkambi) To Treat Cystic Fibrosis

    Cystic Fibrosis Foundation Issues Statement on The New England Journal of Medicine Study on the Benefits of the Ivacaftor/Lumacaftor Combination Drug (Orkambi) To Treat Cystic Fibrosis

  5. Across the Country, Great Strides Are Underway to Find a Cure for Cystic Fibrosis

    Across the Country, Great Strides Are Underway to Find a Cure for Cystic Fibrosis

  6. Vertex's Cystic-Fibrosis Drug Faces Big Test

    Vertex's Cystic-Fibrosis Drug Faces Big Test

  7. Five Consensus Views that Could Prove Wrong in 2015

    Options on this firm's blockbuster cost a little but pay off big.

  8. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

  9. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  10. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.